Brooks Laboratories Limited — Important, 24-01-2025: General Updates

Brooks Laboratories has received in-principle approval from the BSE and NSE for the issuance of 35,33,520 equity shares to the non-promoter group on a preferential basis at an issue price of ₹141.50 each. This capital raising initiative reflects the company’s strategy to boost its financial health and operational capacity. The Fund Raising Committee meeting will take place to decide on the allotment of shares upon receiving the necessary application and allotment funds. Investors should view this move as a significant step towards enhancing liquidity and facilitating growth opportunities, indicating a positive outlook for the company moving forward.